Persevere Therapeutics

Executive Summary

Persevere Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapies for oncology and inflammatory/fibrotic diseases. Its lead asset, misetionamide (GP-2250), is a tumor cell-selective agent with a dual mechanism of action targeting oncogenic transcription factors. The company is initially targeting ovarian and pancreatic cancers, both areas with high unmet medical need. Misetionamide aims to exploit transcription factor vulnerabilities in cancer cells, potentially offering a differentiated therapeutic option. Persevere is privately held, based in Cambridge, MA, and has been advancing its pipeline since its founding in 2019. The company's near-term focus is on advancing misetionamide through clinical development. Upcoming catalysts include the release of initial efficacy and safety data from ongoing Phase 1/2 trials in ovarian and pancreatic cancers, which could validate its novel mechanism and spur partnership or financing interest. As a private entity, Persevere may also seek additional funding to support further clinical expansion. The company's dual focus on oncology and fibrosis provides optionality, though early-stage clinical risk remains. Overall, Persevere represents a high-risk, high-reward opportunity in precision oncology.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 data readout for misetionamide in ovarian cancer40% success
• Q1 2027Initiation of Phase 2 trial in pancreatic cancer70% success
• 2026Series B or partnership financing round50% success